The safety of proton pump inhibitors in pregnancy

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

The safety of proton pump inhibitors in pregnancy. / Nielsen, Gunnar Lauge; Sørensen, Henrik Toft; Thulstrup, Ane Marie; Tage-Jensen, U.; Olesen, Charlotte; Ekbom, Anders.

In: Alimentary Pharmacology and Therapeutics, Vol. 13, No. 8, 08.1999, p. 1085-1089.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Nielsen, GL, Sørensen, HT, Thulstrup, AM, Tage-Jensen, U, Olesen, C & Ekbom, A 1999, 'The safety of proton pump inhibitors in pregnancy', Alimentary Pharmacology and Therapeutics, vol. 13, no. 8, pp. 1085-1089. <http://www.ncbi.nlm.nih.gov/pubmed/10468685>

APA

Nielsen, G. L., Sørensen, H. T., Thulstrup, A. M., Tage-Jensen, U., Olesen, C., & Ekbom, A. (1999). The safety of proton pump inhibitors in pregnancy. Alimentary Pharmacology and Therapeutics, 13(8), 1085-1089. http://www.ncbi.nlm.nih.gov/pubmed/10468685

CBE

Nielsen GL, Sørensen HT, Thulstrup AM, Tage-Jensen U, Olesen C, Ekbom A. 1999. The safety of proton pump inhibitors in pregnancy. Alimentary Pharmacology and Therapeutics. 13(8):1085-1089.

MLA

Nielsen, Gunnar Lauge et al. "The safety of proton pump inhibitors in pregnancy". Alimentary Pharmacology and Therapeutics. 1999, 13(8). 1085-1089.

Vancouver

Nielsen GL, Sørensen HT, Thulstrup AM, Tage-Jensen U, Olesen C, Ekbom A. The safety of proton pump inhibitors in pregnancy. Alimentary Pharmacology and Therapeutics. 1999 Aug;13(8):1085-1089.

Author

Nielsen, Gunnar Lauge ; Sørensen, Henrik Toft ; Thulstrup, Ane Marie ; Tage-Jensen, U. ; Olesen, Charlotte ; Ekbom, Anders. / The safety of proton pump inhibitors in pregnancy. In: Alimentary Pharmacology and Therapeutics. 1999 ; Vol. 13, No. 8. pp. 1085-1089.

Bibtex

@article{e57df020954c11dabee902004c4f4f50,
title = "The safety of proton pump inhibitors in pregnancy",
abstract = "AIM:To assess the safety of proton pump inhibitors during pregnancy.METHODS:Fifty-one pregnant women exposed to proton pump inhibitors around the time of conception or during pregnancy were compared with 13 327 controls without exposure to any prescribed drug in a population-based study based on The Pharmaco-Epidemiological Prescription Database of North Jutland and the Danish Hospital Discharge Registry.RESULTS:Three babies with malformations were found among 38 women exposed to proton pump inhibitors from 30 days before conception to the end of the first trimester. No cases of stillbirth were recorded. Crude relative risks of malformation, low birth weight and preterm delivery were 1.6 (95% CI: 0.5-5.1), 1.8 (95% CI: 0.2-13.0) and 2.3 (95% CI: 0.9-6.0), respectively.CONCLUSIONS:In this population-based follow-up study, we found no substantially elevated risk in terms of malformations, low birth weight or number of preterm deliveries in pregnancies exposed to proton pump inhibitors. However, further monitoring is warranted in order to establish or rule out a potential association between the use of proton pump inhibitors and increased risk of either cardiac malformations or preterm birth.",
author = "Nielsen, {Gunnar Lauge} and S{\o}rensen, {Henrik Toft} and Thulstrup, {Ane Marie} and U. Tage-Jensen and Charlotte Olesen and Anders Ekbom",
year = "1999",
month = aug,
language = "English",
volume = "13",
pages = "1085--1089",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "8",

}

RIS

TY - JOUR

T1 - The safety of proton pump inhibitors in pregnancy

AU - Nielsen, Gunnar Lauge

AU - Sørensen, Henrik Toft

AU - Thulstrup, Ane Marie

AU - Tage-Jensen, U.

AU - Olesen, Charlotte

AU - Ekbom, Anders

PY - 1999/8

Y1 - 1999/8

N2 - AIM:To assess the safety of proton pump inhibitors during pregnancy.METHODS:Fifty-one pregnant women exposed to proton pump inhibitors around the time of conception or during pregnancy were compared with 13 327 controls without exposure to any prescribed drug in a population-based study based on The Pharmaco-Epidemiological Prescription Database of North Jutland and the Danish Hospital Discharge Registry.RESULTS:Three babies with malformations were found among 38 women exposed to proton pump inhibitors from 30 days before conception to the end of the first trimester. No cases of stillbirth were recorded. Crude relative risks of malformation, low birth weight and preterm delivery were 1.6 (95% CI: 0.5-5.1), 1.8 (95% CI: 0.2-13.0) and 2.3 (95% CI: 0.9-6.0), respectively.CONCLUSIONS:In this population-based follow-up study, we found no substantially elevated risk in terms of malformations, low birth weight or number of preterm deliveries in pregnancies exposed to proton pump inhibitors. However, further monitoring is warranted in order to establish or rule out a potential association between the use of proton pump inhibitors and increased risk of either cardiac malformations or preterm birth.

AB - AIM:To assess the safety of proton pump inhibitors during pregnancy.METHODS:Fifty-one pregnant women exposed to proton pump inhibitors around the time of conception or during pregnancy were compared with 13 327 controls without exposure to any prescribed drug in a population-based study based on The Pharmaco-Epidemiological Prescription Database of North Jutland and the Danish Hospital Discharge Registry.RESULTS:Three babies with malformations were found among 38 women exposed to proton pump inhibitors from 30 days before conception to the end of the first trimester. No cases of stillbirth were recorded. Crude relative risks of malformation, low birth weight and preterm delivery were 1.6 (95% CI: 0.5-5.1), 1.8 (95% CI: 0.2-13.0) and 2.3 (95% CI: 0.9-6.0), respectively.CONCLUSIONS:In this population-based follow-up study, we found no substantially elevated risk in terms of malformations, low birth weight or number of preterm deliveries in pregnancies exposed to proton pump inhibitors. However, further monitoring is warranted in order to establish or rule out a potential association between the use of proton pump inhibitors and increased risk of either cardiac malformations or preterm birth.

M3 - Journal article

VL - 13

SP - 1085

EP - 1089

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 8

ER -